peritonleal macrophages could be demonstrated in lower dilutions of the ATS, this activity did Inot appear to correlate with the effects of the sera on listeriosis. The injection of AMS did not enhance the infectious process. In some trials more deaths occurred among mice receiving normal rabbit serum than those receiving AMS. All of the AMS had cytotoxic titers against peritoneal macrophages, and the sera were usually inactive against thymocytes and peritoneal lymphoid cells. Listeria was isolated from fatallv infected mice with nearly equal success in all of the serumtreated groups, and the serum treatments did not appear to alter the patterii of gross lesions. The afferent limb of the immune response was markedly affected by the presence of antibodies to lymphocytes. However, antibodies reacting with inacrophages did not demonstrably enhance the Listeria process, which depends upoIn cellular immunity as the principal means of acquired host defense.
Heterologous antisera against pol)ulations of thymocytes or lymphocytes and macrophages have been utilized in studies to detect the roles of lymphoid cells and macrophages in host responses during infectious diseases (1, 2, 9-11, 18, 23, 24, 27, 33-35) . Results of studies with several infectious agents have emphasized the abilitv of antithymocyte serum (ATS) or antilymphocyte serum (ALS) to suppress cellmediated resistance (2, 11) . Mackaness and Hill (23) and Lane and Unanue (18) reported that rabbit antimouse lymphocyte globulin completely suppressed the immune expression of passively transferred Listeria-immune lymphoid cells. The effects of antimacrophage serum (AMS) have not been as extensively investigated. In the present study, antisera were prel)ared against purified populations of thymocytes and peritoneal macrophages from mice. The survival PEARSON 
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The inoculated mice were observed each day at 3-to 8-h intervals during the periods of extensive mortalities. The mean lethal dose (LD50) of L.
monocytogenes for Balb/c mice was determined at the time of trial I (13) . The estimated time of death (T60) for each group of animals after inoculation with L. monocytogenes was determined by the graphic method of Litchfield (19) .
ATS. Thymuses from weanling Balb/c mice were collected aseptically. The pooled intact thymuses were rinsed briefly in distilled water to lyse erythrocytes adhering to external surfaces. The glands were then rinsed with Eagle minimum essential medium (MEM) containing 10% prenursing calf serum (PNCS) and 5 U of heparin per ml. The thymuses were diced with scissors and then forced through a 60-mesh wire screen. The resulting suspension was then passed through a loosely packed column of glass wool to remove clumps of cells. The cells were put onto plastic, tissue culture dishes (60-mm diameter) and incubated at 37 C for 1 h in a chamber containing 5% C02 in humid air. Nonadherent cells were then aspirated from the dishes and washed twice with MEM to remove the PNCS by using a centrifugal force of 500 X g for 10 min. The cells were counted in a hemocytometer. As assessed by trypan blue dye exclusion (4), 85 to 95% of the cells were viable. Seven rabbits were injected intravenously with thymus cells in doses ranging from 1.4 X 118 to 1.9 X 109 cells. Antigen was administered twice with a 14-day interval between injections. The harvested antisera were designated as ATS 1-7. The "two-pulse" immunization procedure was used in order to minimize the production of undesired antibodies such as red-cell agglutinins (16) . Serum was first collected on day 7 after the cell injections. Each serum was filtered through a 0.45-jum filter membrane (Millipore Corp., Bedford, Mass.), heated at 56 C for 30 min, and then stored at -20 C.
AMS. Peritoneal macrophages from unstimulated Balb/c mice were used to produce AMS in four rabbits (AMS 1 to 4). The procedures for producing AMS paralleled those described by Hirsch et al. (12) . The peritoneal cells were collected in Eagle MEM supplemented with 10% PNCS. The culturing medium was changed after 1, 24, and 48 h of incubation at 37 C in a chamber containing 5% CO2 in humid air. After 4 days of incubation the surviving adherent cells were scraped from the culturing dishes with a rubber policeman, suspended in MEM free of PNCS, and counted. Over 95% of the cells were classified as macrophages by light microscopy examination. Each rabbit was injected intravenously twice with doses of macrophages ranging from 6.3 X 106 to 1.2 X 107. There was a 14-day interval between injections.
Three additional AMS were prepared (AMS 5 to 7) by using cells derived from mice that had been stimulated by the intraperitoneal injection of 3 ml of Thioglycollate medium (Difco Laboratories, Detroit, Mich.). The peritoneal exudate cells collected 6 to 8 days later were partially purified before injecting them into rabbits. Freshly collected exudate cells suspended in MEM with 10% PNCS and 5 U of heparin per ml were plated onto plastic, tissue culture dishes. The cells were incubated for 30 min at 37 C in a chamber containing 5% C02 in humid air. Nonadherent cells were then washed from the dishes with several rinses of MEM. The adherent cells, of which 2% or less were polymorphonuclear leukocytes, were scraped from the plates with a rubber policeman. They were then suspended in MEM and counted. Injections of macrophages, as previously described, were given to three rabbits, with doses of cells ranging from 6.3 X 106 to 4.7 X 107. The AMS were first collected 7 days after the second injection of cells. They were processed and stored as described for the ATS.
Leukocytotoxicity assays. Assays were made as suggested by Boyse (4) . Thymocyte suspensions were prepared as described for the production of ATS. Peritoneal macrophages were collected from mice 6 to 8 days after an intraperitoneal injection of 3 ml of sterile Thioglycollate medium (3) . Either commercial, guinea pig complement or rabbit complement was used. Rabbit complement was derived from pooled, fresh rabbit serum which was adsorbed with mouse spleen cells before use. For each assay a freshly thawed sample of complement was used from the pool that was stored at -70 C. Twofold, serial dilutions of the ATS or AMS were tested. The viability of the test cells was assessed at X400 magnification with bright-field optics. A reaction was judged to be cytotoxic when more than 50% of the cells were stained by trypan blue. The log2 of the reciprocal of the greatest dilution of serum which caused cytotoxicity was designated as the titer.
RESULTS
Leukocytotoxicity titers. The presence of antibodies in the ATS and AMS that combined with meinbrane antigens on thymocytes, lymphocytes, and peritoneal macrophages was detected by leukocytotoxicity assays. Titers are recorded in Table 1 . The sera were not cytotoxic in the absence of complement. Cells incubated for 2 h in the presence of inactivated (56 C, 30 min) ATS, AMS, and normal rabbit serum (NRS) continued to exclude the trypan blue dye. Loss of membrane integrity was apparent, however, when guinea pig or rabbit complement was added to mixtures containing reactive serum. The ATS proved to be active against thymocytes with titers of six sera ranging from 27 0 to 2"l 5. The titer declined to 25.0 in a pooled serum which was collected 190 days after antigen injection.
The method used for assaying cytotoxic activity against mouse peritoneal exudate cells allowed for, the simultaneous detection of activity directed toward macrophages and nonadherenlt lymphoid cells. Peritoneal macrophages settled onto the glass and became adherent during the hour which preceded the addition of anti- I ). As exl)ected, the ATS were cytotoxic for the lymnl)hoid cells, but four out of five sera tested were also cytotoxic for macrol)hages. Titers for the latter activity were always 1 to 3 twofold (lilutiolls lower thaji the activity againist the lyml)hoid cells. Thus, with the appropriate serum dilutioni, onie could demonstrate cytotoxicity for lymphoid cells while the macrophages remained unaffected (Fig. 1) .
All of the AMS contained high titers of cytotoxic antibodies to macrophages (Table 1) . Low titers of antibodies reactive with lymphoid cells were detected in two of the three sera prepared after partial l)urification of Thioglycollatestimulated peritoneal cells (AMS-5 and AMS-7).
Reaction with lymphoid cells was not detected when AMS was lproduced by the injection of macrophages that had been cultured in vitro for 4 days (Fig. 2) .
The NRS were not cytotoxic for any of the cells. These sera came from rabbits which were subsequently immunized to produce ATS Table 2 .
In trial I the mice were inoculated intraperitoneally with 5.7 X 104 L. monocytogenes (2 X LD50) oIn day 0 and 0.25 ml doses of serum 1 day before and 2 days after the bacteria. The experiment compared groups of mice receiving an ATS, an AMS, a NRS (preimmunization serum for ATS-1), and a group with no serum treatment ( Table 2) . Mortalities accumulated rapidly in the ATS-treated group (T50 = 4 days) and reached 100% by 6 days (Fig. 3) . In contrast, the group receiving no serum had only a 57% mortality, and these deaths did not occur as rapidly (T50 = 6.8 days). The NRS group responded nearly the same as the no-serum group, Trial IV was planned to test the effects of initensive serum treatment prior to infection. Sera were injected in 0.2 ml doses 6, 4, and 1 day before inoculating 2.9 X 104 bacteria (assumed 1.0 X LD50). Interpretations of the experiment were made difficult, because no mortality occurred in the groul) without serum treatment, and it was concluded that the Listeria culture had declined in virulence (Table 2) . Some mortalities occurred among the treated groups. The earliest deaths were observed in an ATS-treated group, but the greatest mortality (60%) was reached in an AMS-treated group. The pooled ATS (ATS 1 to 3) collected 190 days after immunization had a low cytotoxicity titer for thymocytes and demonstrated no enhancement of the infectious process.
On day 8 after initiating the Listeria infection, a fourth dose of serum was injected. The purpose was to determine whether the resistance of the animals could be reduced in the event that some mice still harbored live bacteria in their tissues. Several precipitous deaths occurred within 12 h of the injections of sera. Spleens of the dead mice were engorged with blood, and efforts to recover L. monocytogenes from the tissues were uniformly negative. The deaths were attributed to hypersensitivity phenomena associated with the previous injections of rabbit serum proteins.
Prior to the initiation of trial V, the Listeria culture was passaged twice through normal mice to enhance virulence. In trial V the mice again received 0.2 ml of serum at 6, 4, and 1 days before infection with 2.3 X 104 Listeria organisms. Mortality in the ATS-treated groups reached 87% and 100%, whereas the group without serum had only a 37% mortality ( Table 2 ). The first deaths again occurred in the ATS-treated mice. Animals receiving AMS or NRS (pooled preimmunization sera from rabbits used to produce ATS 5, 6, and 7 and AMS 5, 6, and 7) had death losses higher than that of the group receiving no serum. The specific role of antibodies to macrophages was not apparent, however, because the groups injected with NRS experienced more deaths than the AMS-treated animals. The experiment was terminated after 25 days.
Trial VI was designed to test the role of serum treatment in animals that might have carried live bacteria in their tissues after a sublethal primary infection. Mice were first iinoculated with 1.4 X 104 Listeria cells, and 6 days later they were injected with 0.2 ml of the appropriate serum.
Groups of five animals each were treated with the same sera used in trial V. No mortalities occurred prior to or after the injections of sera during 14 days of observation. Mice dying during the course of the various trials were examined for gross lesions and subjected to bacteriological culturing to detect any patterns relating to specific serum treatments. Livers, spleens, kidneys, and heart blood were cultured. Gross lesions were observed primarily in livers and spleens, and L. monocytogenes was most consistently recovered from those tissues. The various serum treatments did not appear to affect this general pattern. DISCUSSION Antigenic stimulation by L. monocytogenes commits some lymphoid cells to synthesize humoral antibodies whereas others, probably of thymic origin, are destined for participation in reactioins of cell-mediated immuinity. The latter cells are presumed to bring about the altered state of macrophages functioning in antimicrobial cellular immunity (37) . The phenomena of cellular immunity are considered to play a central role in mediating resistance to L. monocytogenes in mice (22, 38) . Conversely, antibodies alone do not engender resistance when transferred to normal mice (25, 29) . Nevertheless, in the natural disease process humoral antibody production is a part of the immune response (28) , and its role in consort with cellular immunity has yet to be clarified.
The brief time required to marshall acquired resistance against L. monocytogenes in mice makes this experimental model of special interest. When live bacteria are inoculated in sublethal numbers, they replicate primarily in the spleen and liver for 3 to 4 days, and then rapidly diminish in numbers as they are destroyed in macrophages (21) . When lethal doses of bacteria are given, toxic effects on phagocytic cells and the heart (17) may be the direct cause of mortality.
In the current experiment, the afferent limb of the immune response was depressed by the administration of immunosuppressive sera. Host resistance to L. monocytogenes was most noticeably decreased when effective ATS was administered near the time of the primary infection. Mice treated with ATS experienced earlier, as well as more extensive, mortality than the mice not treated with serum. The ATS mediated removal, and destruction of the circulating lymphoid cell population apparently included those lymphoid cells which were becoming immunologically committed after antigenic stimulation by L. monocytogenes.
Other investigators have found that passive antilymphoid antibodies impair immune responses to infectious agents. The survival tiine of mice infected with Mycobacterium lepraemurium was decreased when treated with antilymphocyte globulin (ALG), and ALG treatment obliterated the protective immunity usually provided by bacillus Calmette-Guerin immunization in mice (9) . Histoplasma capsulatum became more invasive and proliferative in ALS-treated mice (1). Grogan (10) found that treating rats with ALS more than 72 h after a Pseudomonas infection had been initiated did not increase the death rate, whereas ALS administered within 48 h of the infection did increase mortality. Rethy and Pad4nyi (33) significantly suppressed the development of immunity in mice treated with ALS a few days before or after immunization with Erysipelothrix insidiosa vaccine, but ALS had no effect if the challenge infection was initiated after antibodies to the bacterium had appeared.
Antibody response by mice to injected foreign serum proteins was to be expected. In trial IV the mice received rabbit serum on days 6, 4, and 1 prior to infection. When a fourth serum injection was made 8 days after infection (14 days after the first dose of serum), many of the mice died within 12 h. The clinical signs and lesions were suggestive of a systemic Arthus reaction. The hypersensitive state of the mice indicated that the cytotoxic role of the injected antibodies would have been lost at some time prior to day 14. Treatment of mice with NRS (for most trials these were preimmunization sera from rabbits used to produce ATS and AMS) was associated with increased susceptibility to L. monocytogenes when compared with mice that were not injected with a serum. Rethy and Padinyi (33) reported similar effects from NRS in experimental Erysipelothrix insidiosa infections in mice. They attributed the effect to antigenic competition between the foreign protein antigens and the bacterial antigens.
There was apparently little effect on the efferent limb of the immune response from the serum treatments. In trial VI the mice were treated with ATS, AMS, and NRS 6 days after the initiation of a sublethal infection. The intent was to determine whether injury to lymphocytes or macrophages could unmask residual bacteria that might have survived in the tissues. The number of viable Listeria are known to diminish rapidly after the 4th day (21), but small numbers of bacteria may persist for a time. The presence of lesions at this subacute stage are indicative of residual infection (6) . No deaths were associated with any of the serum treatments in trial VI.
Furthermore, Mackaness and Hill (23) (12, 30, 39) and the functional capabilities of macrophages (7, 15, 20, 32, 36 
